Awards duration ranges from one to three years. As with all MJFF grants, full funding is dependent on fulfillment of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the PD research community. The selection of program awardees was made exclusively by the Foundation under its standard peer-review process.
The Michael J. Fox Foundation
Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded $128 million in research to date.
About EMD Serono
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a
leader in the US biopharmaceutical arena, integrating cutting-edge science
with unparalleled patient support systems to improve people's lives. The
company has strong market positions in neurodegenerative diseases, with
Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R)
(somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNA
origin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) for
injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R)
(follitropin alpha for injection), Luveris(R) (lutropin alfa for injection)
and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With
a clear focus on the patient and a leadership presence in the
biopharmaceutical industry, EMD Serono's US footprint continues to grow,
with more than 950 employees around the country and fully integrated
commercial, clinical and research operations in the company's home st
|SOURCE EMD Serono, Inc.|
Copyright©2008 PR Newswire.
All rights reserved